(1-13 g/l; CI, 0-95 to 1-31; p<001) and normal controls (0-88 g/l; CI, 0-82 to 0-94; p<0-05) ( Fig  IA) . Plasma C4 (0-20 g/l; CI, 0-16 to 1-24) was also reduced when compared with uninfected patients (0-28 g/l; CI, 0-20 to 0-36; p<0 05), but not when compared with normal controls (0-21 g/l; CI, 0-17 to 0-25) (Fig IB) . The plasma factor B concentration in SBP patients (0-19 g/l; CI, 0-15 to 0-23) was not significantly different from that in patients without SBP (0-24 g/l; CI, 0-20 to 0-28) or controls (0-18 g/l; CI, 0 16 to 0-20) (Fig  1C) . In uninfected patients compared with controls, there was no significant difference in plasma C3 and C4 but there was a statistically significant (p<0-01) increase in plasma factor B in these patients (Fig 1C) .
PLASMA COMPLEMENT ACTIVATION INDICES
Calculation of activation ratios showed that plasma C3 activation was significantly greater in patients with SBP (14-0 (1-71)) than in normal subjects (0-53)) and patients without SBP (8-11 (0 70)) (p<OOl) (Fig 2A) . Plasma C4 activation was also greater in SBP patients than in uninfected patients (37 3 (4-1) v 22-2 (2-6), p<O0 1), but there was no significant difference between SBP patients and normal controls (33 0 (4 6)) (Fig 2B) . There was no significant difference in plasma factor B activation between SBP patients (168 (25 0)) and patients without SBP (195 (21-7)) or normal controls (166 (10-2)) ( Fig 2C) .
Patients without SBP showed no significant difference from normal controls for activation of C3, C4, or factor B (Fig 2A-C) .
ASCITES C3, c4, AND FACTOR B Ascitic concentrations of both C3 and factor B were higher in patients without SBP (0-37 g/l; CI, 0-23 to 0-51 and 0-11 g/l; CI, 0 05 to 0-17 respectively) than in patients with SBP (0-08 g/l; CI, 0-06 to 0-10 and 0 03 g/l; CI, 0 01 to 0 05 respectively, p<0O5). There was no significant difference in the ascitic concentrations of C4 (0-07 g/l; CI, 001 to 013 and 003 g/l, CI, 001 to 0-05 respectively).
ASCITES COMPLEMENT ACTIVATION INDICES
Calculation of activation ratios showed that ascitic C3 activation was significantly greater in patients with SBP (79 1 (16 39)) than in uninfected patients (36 1 (6 35), p<O 05) (Fig 3A) . When patients with SBP were compared with uninfected patients, this difference was not present for ascitic C4 activation (241 (51 4) v 336 (5414)) (Fig 3B) or ascitic factor B activation (2140 (724) v 1220 (240)) (Fig 3C) .
Clinical grading of the patients by the Pugh's classification showed no significant differences in the severity of the liver disease between patients with SBP and those without infection (Table II) . Seven These findings are compatible with those of previous studies which showed normal or reduced C3 concentrations in patients with chronic liver disease. [13] [14] [15] [16] Although details of whether infection was present were not given, the decrease was generally less noticeable in patients with alcoholic liver disease than in those with liver diseases of other aetiologies.4 16 Since, in the present study, most patients had alcoholic cirrhosis with superimposed alcoholic hepatitis, it is possible that the finding of increased plasma C3, C4, and factor B concentrations in a number of subjects without SBP could be secondary to increased synthesis as part of the acute phase response in patients with alcoholic hepatitis. It is of interest that although all our patients had severely decompensated liver disease with poor synthetic function as judged by low serum albumin and prolonged prothrombin time, hepatic synthesis ofC3, C4, and factor B was not impaired. This finding contrasts with early studies which compared reduced complement concentrations with impaired synthetic function and showed a positive correlation. '6 17 In two recent studies, patients with low ascitic C3 concentrations were shown to be more likely to develop SBP while in hospital, although a similar relation between C4 and SBP was not present.5 8 However, in both studies the patients in whom SBP later developed had more severe liver disease as judged by Child's grading, and the increased likelihood ofdeveloping SBP could have been a reflection of the severity of underlying liver disease. In the present study, infection was already present when the ascites in which complement concentrations were measured was obtained -it is therefore possible that the presence of infection could have worsened the abnormalities in the prothrombin time and serum bilirubin, which are included as factors in Child's grading of severity of disease, and this would have made it less likely that our patients with SBP had more severe underlying liver disease.
A further consideration is the possible effect that diuresis and paracentesis could have on the complement concentrations in ascites. Runyon et al reported that complement activity in the serum and ascites ofpatients undergoing diuretic treatment alone was higher than in patients in whom repeated paracenteses were performed. '9 In the present study, samples were obtained before therapeutic paracentesis was performed.
Nevertheless, it is possible that the effects of diuretics on the patients could have influenced the results. Similarly, it is possible that the contrast between plasma and ascites complement concentrations could be influenced by the effect of infection on the permeability of peritoneal capillaries. In the study by Such, however, a direct correlation between serum C3 and ascitic fluid C3 was observed. It is of interest that in Such's study the ascitic fluid protein was significantly less in the patients who developed SBP, a feature also present in the patients reported here, even although by Child's grading the underlying liver disease was of similar severity and there was no difference in the serum albumin concentrations in the infected and uninfected patients (Table I) .I
In common with other recent studies, the possible effect of decreased hepatic clearance on complement components has not been taken into account.4'5 However, animal models suggest that complement catabolism takes place in other organs such as the lung, spleen, and kidney and it is therefore unlikely that impaired hepatic clearance would cause a rise in plasma complement fragment values. 20 In patients without SBP compared with normal controls, complement activation showed no significant differences. This argues against a mechanism whereby complement activation is involved in the pathogenesis of the underlying liver disease, although this has been suggested as a possible mechanism of cell damage in alcoholic liver disease.2' However, it is possible that in our severely decompensated patients there was little continuing hepatocellular damage and clues as to the pathogenesis may not be present.
These findings suggest that the decrease in plasma complement values present in advanced liver disease could be indicative of infection and are unlikely to be affected by impaired synthetic capacity of the liver. Our findings also show that SBP is accompanied by activation of the classical complement pathway in plasma, highlighting the systemic nature of the infection and underline the results of previous studies which have shown that patients with a low ascitic protein are at highest risk of developing SBP. 
